Suggestions
Ian Napier
Regulatory Affairs Manager at MSD Australia & New Zealand
Professional Background
Ian Napier is a highly accomplished Regulatory Affairs Manager specializing in Oncology, currently making waves at MSD Australia & New Zealand. With extensive experience in regulatory strategy and execution, Ian has shown a remarkable ability to manage complex applications and approvals in the fast-paced pharmaceutical and biotechnology landscape. His involvement in key projects highlights his expertise in navigating regulatory pathways, particularly in the field of oncology.
Ian has had a stellar career, marked by his instrumental role in securing over ten extensions of indications for a lead immuno-oncology product. He achieved the prestigious distinction of being the first to gain approval under the Therapeutic Goods Administration's (TGA) Provisional Approval pathway, which is a testament to his expertise in regulatory affairs. Additionally, he successfully spearheaded the first regulatory approval in Australia through Project Orbis, collaborating with international regulatory bodies including the FDA and Health Canada (HC).
His pioneering efforts also led to the approval of Australia's first tumour-agnostic oncology medicine, further showcasing his commitment to innovation and excellence in the field. Ian’s success includes securing four Priority Review extension of indications approvals, demonstrating his strategic insight and ability to expedite crucial therapeutic solutions to market. Moreover, he implemented a streamlined process for Good Manufacturing Practice (GMP) clearance applications, resulting in an impressive 100% right-first-time success rate, significantly enhancing the efficiency of application submissions in his team.
As a leader in regulatory affairs, Ian oversees the regulatory strategy and execution for multiple portfolios, including oncology, HIV, lipid therapies, and anaesthetics. His role entails the preparation and submission of various regulatory applications and notifications that adhere to strict governmental and clinical standards, fostering a seamless pathway for impactful therapies in Australia and New Zealand.
Education and Achievements
Ian's educational foundation is grounded in rigorous scientific training. He earned a Doctor of Philosophy (PhD) in Neuroscience from the esteemed University of Sydney, equipping him with a deep understanding of the biological intricacies relevant to drug development and regulatory requirements. Prior to this, he obtained a Bachelor of Science (B.Sc.) degree with Honours I in Biochemistry and Molecular Biology from Macquarie University, emphasizing his strong academic background and dedication to the life sciences.
Ian's expertise is not limited to his impressive professional history but extends into meaningful contributions to organizational commitments. He is an active member of the Medicines New Zealand Regulatory Technical Committee and has prepared and submitted critical responses to various industry consultations, including issues surrounding serialisation in Australia and the Therapeutic Products Bill in New Zealand. His dedication to regulatory compliance and ongoing improvement within the industry reflects his commitment to public health and safety.
Achievements
Some of Ian's specific achievements include:
- Securing key approvals in more than ten extensions of indications for lead immuno-oncology product.
- Becoming the first professional to attain an approval under the TGA's Provisional Approval pathway.
- Successfully obtaining the first regulatory approval through Project Orbis in Australia, in collaboration with the FDA and Health Canada.
- Achieving approval for Australia's first tumour-agnostic oncology medicine, demonstrating his forward-thinking approach in the oncology sector.
- Gaining four Priority Review extension of indications approvals, highlighting his efficiency and strategic insight.
- Implementing new processes that resulted in an unprecedented 100% right-first-time applications for GMP clearance.
Ian Napier is a prime example of how dedication, strategic vision, and a commitment to collaboration can drive significant advancements in the field of regulatory affairs, particularly in oncology. With an impressive educational background and notable career achievements, he continues to influence the industry positively and make vital contributions to the healthcare landscape in Australia and New Zealand.
